News and Trends 2 Sep 2022 Ibex reports positive outcomes for AI-supported diagnosis of breast cancer Ibex Medical Analytics have just announced positive outcomes for its Galen Breast solution in diagnosing multiple cancer types and further expanding its portfolio for breast cancer diagnosis. The CE-marked artificial-intelligence is generally available as the company partners with laboratories, hospitals and health systems across Europe. Ibex Medical Analytics says Galen Breast supports improved quality and […] September 2, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 2 Sep 2022 Psoriasis pustules disappear in over half of patients using Boehringer Ingelheim drug More than half of patients treated for psoriasis with an intravenous injection showed no visible pustules just one week after receiving treatment. Boehringer Ingelheim announced today (September 2) that the U.S. Food and Drug Administration (FDA) has approved the first treatment option, SPEVIGO, for generalized pustular psoriasis (GPP) flares in adults. SPEVIGO is a novel, […] September 2, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 2 Sep 2022 Cancer drug for children and young people with glioblastoma given to patients in study Clinical-stage bio company, Onxeo, has announced that the first patients have been enrolled and treated in a phase 1b/2 clinical study. The study is to evaluate the efficacy and tolerability of AsiDNA2, a DDR inhibitor combined with radiotherapy in children, adolescents or young adults with relapsed high grade glioma (HGG). Onxeo, which focuses on drugs […] September 2, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 2 Sep 2022Beyond Biotech podcast 12: Gate Neurosciences, Oncolyze, 3Brain This week’s podcast guests are Mike McCully, CEO of Gate Neurosciences; Steven Evans, CEO and co-founder of Oncolyze; and Philipp Markolin, scientific marketing specialist at 3Brain. We also have our weekly chat with global commercial real estate services company JLL, and this week it’s a chat with Amber Schiada, head of life sciences research in […] September 2, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 2 Sep 2022 Manus Bio receives additional funding to fight malaria with biotech U.S. biomanufacturer Manus Bio has received a fourth award from the Bill & Melinda Gates Foundation to develop a scalable production route for the potential antimalarial drug, artemisinin. The $2 million award will enable Manus Bio to begin scaling up the biological process it has developed towards the chemical intermediate, dihydroartemisinic acid. Economical and scalable […] September 2, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 New discovery could lead to drug development for brain cancer According to researchers, a study at Tel Aviv University in Israel effectively eradicated glioblastoma, a highly lethal type of brain cancer. The researchers achieved the outcome using a method they developed based on their discovery of two critical mechanisms in the brain that support tumor growth and survival: one protects cancer cells from the immune […] September 1, 2022 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Proxidrugs: a new tool to fight pathogens? Scientists at the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP in Germany are working with partners to develop a new drug class. Proxidrugs (or proximity-inducing drugs) utilize cells’ waste disposal system as potential new treatments for cancer, infections and Alzheimer’s disease. Aimo Kannt, head of drug discovery and preclinical research at Fraunhofer ITMP in […] September 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Study of injection to treat schizophrenia to begin after $3M payment received A phase 3 clinical trial for an injection to treat patients with schizophrenia has been initiated after a $3 million payment was received by MedinCell. Teva Pharmaceuticals made the decision to start the trial for mdc-TJK this week (August 29). Schizophrenia is a serious mental disorder in which people interpret reality abnormally. Schizophrenia can produce a […] September 1, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Brainomix awarded tender to deploy AI stroke imaging across whole of Hungary Artificial intelligence (AI) stroke imaging will be deployed across centers in Hungary after Brainomix was awarded a national tender. The company was granted the tender for all stroke centers in the country as part of the National Institute for Health Development initiative to improve stroke care. Following a competitive process, the five-year program that was […] September 1, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Provention Bio looks to advance diabetes drug through $125M loan U.S. biopharma company Provention Bio, Inc. has secured a term loan facility of up to $125 million with Hercules Capital, Inc. ahead of the company’s potential launch of teplizumab. The BLA for teplizumab, Provention Bio’s lead investigational drug candidate, for the delay of progression to stage 3 clinical type 1 diabetes in at-risk individuals has […] September 1, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 License agreement signed allowing drug to treat mycosis fungoides to expand in Asia, Australia and the Middle East A license agreement has been signed between Helsinn Group and Juniper Biologics further widening the scope for distribution of T-cell lymphoma treatment, LEGADA. The license signifies a supply agreement to register, distribute, promote, market and sell the drug in Australia, Asia and the Middle East as a topical treatment of the mycosis fungoides-type cutaneous T-cell […] September 1, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Sanofi’s first treatment in the U.S. approved for adults and children with ASMD A rare, inherited disease that affects the body’s ability to metabolize fat, cholesterol and lipids within cells can now be treated by Xenpozyme, a drug approved by the U.S. Food and Drug Administration (FDA). Adults and children with non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD) can now take healthcare company Sanofi’s Xenpozyme […] September 1, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email